Javier Munoz, MD, MS, FACP: The course of mantle cell lymphoma is many times convoluted. This is an aggressive disease. The median overall survival when incorporating intensive therapy is 8 to 10 years, and shorter survival times are seen with less intensive therapy. For the relapsed/refractory setting of mantle cell lymphoma, there are 3 BTK [Bruton tyrosine kinase] inhibitors currently FDA approved: ibrutinib, acalabrutinib, and zanubrutinib. Other options include bortezomib, the immunomodulator lenalidomide, and the BCL2 inhibitor, venetoclax.
Patients who are relapsed or refractory after a BTK inhibitor have a very ominous prognosis, with a survival of maybe 13 months. Hence, several trials have been conducted trying to salvage this population of patients. The inclusion criteria for ZUMA-2 was for patients with relapsed or refractory mantle cell lymphoma after up to 5 previous therapies, and all patients needed to have received a previous BTK inhibitor. Needless to say, these patients face an unmet need in lymphoma, and the ZUMA-2 trial did allow patients with high-risk features to enroll, including patients with high MKI67, TP53 abnormalities, high MIPI [Mantle Cell Lymphoma Prognostic Index] scores, and blastoid or pleomorphic histologies. These patients are the sickest of the sick and have historically done very poorly with standard chemotherapy.
We know that chimeric antigen receptor, or CAR, T-cell therapy, such as axicabtagene ciloleucel, or axi-cel for short, has displayed efficacy in patients with relapsed or refractory aggressive B-cell lymphomas. This includes diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. KTE-X19 is an anti-CD19 CAR T-cell therapy, meaning you are re-educating those T cells to target cells that express CD19, which is present across the board in multiple B-cell malignancies including mantle cell lymphoma. The KTE-X19 data in the ZUMA-2 trial was recently presented by Dr Michael Wang at medical conferences. Furthermore, KTE-X19 is particular in the way that it’s produced in a manufacturing process that removes circulating CD19-expressing malignant cells that could potentially be present in patients with leukemia or lymphomas. The removal of these CD19 malignant cells decreases the chances of exhaustion of anti-CD19 CAR-T cells during the manufacturing process, making it more seamless.
ZUMA-2 was a phase 2 trial that analyzed data for 74 patients enrolled. The results showed 93% of patients had an objective response, and 67% of patients had a complete response. KTE-X19 was manufactured for 71 patients and administered to 68 patients. Hence, when you look at the intention-to-treat analysis, the objective response was 85% and complete response was 59%, which is still impressive.
At 12 months, the estimated progression-free survival and overall survival were 61% and 83%, respectively. Very similar to the CAR T cells previously approved for aggressive B-cell lymphomas, serious and life-threatening toxic effects were consistent with those reported with those of other constructs. The main toxicities for CAR T-cell therapies, in general, are cytokine release syndrome and neurological events. Grade 3 or higher cytokine release syndrome and neurological events occurred in 15% and 31% of patients, respectively, when KTE-X19 was used.
Transcript edited for clarity.
Case: A 66-Year-Old Woman With Mantle Cell Lymphoma
History
Currently
Liso-Cel Delivers Deep, Durable Responses in R/R MCL
January 11th 2024High complete response rates and low incidences of cytokine release syndrome and neurological events were observed when patients with relapsed or refractory mantle cell lymphoma were treated with lisocabtagene maraleucel.
Read More
ZUMA-18 Study Shows Brexu-cel's Therapeutic Potential in MCL
January 3rd 2024In an interview with Targeted Oncology, Andre Goy, MD, discussed the potential of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory mantle cell lymphoma and how 2 studies provide support for use of the agent in this patient population.
Read More